Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst

Musculoskeletal System Disorders Market Research Report Information By Type (Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Psoriatic Arthritis, Ankylosing Spondylitis), Treatment (Biologics, Corticosteroids, Physical Therapy, Protein Therapy, Composite Grafts) and End User (Hospitals and Clinics, Ambulatory Surgical Centers) - Forecast to 2032


ID: MRFR/HC/6760-HCR | 111 Pages | Author: Kinjoll Dey| April 2024

Musculoskeletal System Disorders Market Forecast


The musculoskeletal system disorders market is expected to reach USD 6.07 Billion by 2032 at 6.8% CAGR during the forecast period 2023-2032.


Musculoskeletal System Disorders Market Synopsis


The number of musculoskeletal system disorder cases is increasing globally, fueling musculoskeletal system disorder market growth. Musculoskeletal system disorders are the second-highest contributor to global disability and an estimated 20%–33% of people across the globe live with a painful musculoskeletal condition.


Musculoskeletal disorders are most common in low- and middle-income countries and these disorders require lifelong care to manage.


Musculoskeletal System Disorders Market Influencer


Rising prevalence of musculoskeletal disorders and increasing reimbursement offered to patients by health insurance providers.


Musculoskeletal System Disorders Market Drivers



  • Growing global geriatric population.



  • Change in lifestyle habits leading to bad posture, which is increasing the prevalence of musculoskeletal system disorders.



  • Increasing research and development of new drugs to treat musculoskeletal disorders. For instance, in 2017–2018, the National Institute of Health Research (NIHR) spent approximately USD 13.46 million (GBP 11.1 million) on research on musculoskeletal disorders.



  • Rising prevalence of work-related musculoskeletal disorders. For example, the prevalence in the fiscal year 2017–2018 was about 469,000 in the UK.



  • Rising awareness of advanced treatment for musculoskeletal disorders.



  • Launch of new medication to manage the symptoms of chronic musculoskeletal system disorders.


Musculoskeletal System Disorders Market Restraints



  • High treatment costs.



  • Availability of alternative therapies such as traditional medicine and physiotherapy



  • Need for specialized equipment to diagnose and treat musculoskeletal system disorders.


Musculoskeletal System Disorders Market Segmentation


By Type



  • Rheumatoid Arthritis: The largest segment of the musculoskeletal system disorder market, rheumatoid arthritis afflicts almost 1% of the entire global population and is three times as likely to afflict women than men.



  • Osteoarthritis: This disorder generally afflicts elderly people. As of 2018, about 9.6% of men and 18% of women over 60 had symptomatic osteoarthritis worldwide and over a quarter of those afflicted could not perform daily activities.



  • Osteoporosis: The fastest-growing segment, over 75 million people suffer from osteoporosis in Europe, the US, and Japan. This number is growing in developing countries and the disorder is responsible for millions of fractures worldwide. By 2050, osteoporosis is expected to be responsible for a 310% increase in hip fractures for men and a 240% increase for women, as compared to rates in 1990.



  • Psoriatic Arthritis: This autoimmune disorder afflicts roughly 3 out of every 10 individuals who have psoriasis. With over 100 million people afflicted globally with psoriasis, psoriatic arthritis afflicts almost 30 million individuals.



  • Ankylosing Spondylitis: The tendency to develop this condition is genetic, with males twice to three times more likely to be afflicted than women.



  • Fibromyalgia: A very common ailment, about 80%–90% of sufferers of fibromyalgia are women.



  • Others: This segment covers musculoskeletal disorders such as tendinitis and carpal tunnel syndrome.


By Treatment



  • Biologics: The fastest-growing segment, biologics find increasing application in the treatment of rheumatoid arthritis. A rise in the number of FDA approvals for biologics to treat musculoskeletal system disorders is a key factor for the growth of the segment.



  • Corticosteroids: The largest segment, corticosteroids are the preferred treatment for many musculoskeletal system disorders as they reduce inflammation and suppress immune system activity.



  • Physical Therapy: Used to manage almost all chronic musculoskeletal system disorders, physical therapy is prescribed in conjunction with medication.



  • Extracorporeal Shock Wave Therapy: Used to manage pain, this therapy excels in providing fast-acting relief without the use of painkillers. Used extensively in managing musculoskeletal system disorders.



  • Protein Therapy: A novel method used to combat several musculoskeletal system disorders; it involves the ingestion of protein via changes in diet and artificially produced proteins.



  • Synthetic Bone Graft: An expensive and complex treatment option, synthetic bone grafts have been used to replace bones made too brittle by osteoporosis and other musculoskeletal system disorders.



  • Composite Grafts: Used for several bone replacement and repair procedures.



  • Demineralized Bone Matrix: The treatment method is used in bone transplants where the biological activity of the graft is more important than its mechanical properties.



  • Others: This segment covers alternative treatment methods such as gene therapy and chiropractic care.


By End User



  • Hospitals and Clinics: The largest segment, hospitals and clinics are usually the primary points for diagnosis, treatment, and rehabilitation of individuals afflicted with musculoskeletal system disorders. Growing awareness and increasing efficiency of musculoskeletal system disorder treatment are projected to drive the growth of this segment during the forecast period.



  • Ambulatory Surgical Centers: A small segment, these centers provide immediate pain relief and rudimentary surgical care.



  • Others: This segment includes home care and senior citizen centers.


By Region



  • Americas: The largest regional market, the prevalence of musculoskeletal system disorders is high in the Americas; the region also has a well-established healthcare industry.



  • Europe: An increasing geriatric population is leading to a rise in the number of musculoskeletal system disorder cases.



  • Asia-Pacific: The fastest-growing regional market, Asia-Pacific is seeing a surge in the number of people afflicted with musculoskeletal system disorders due to bad posture brought on by lifestyle changes, aging, and genetic predisposition.



  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and a very young population.


Musculoskeletal System Disorders Market Key Players



  • AB Science (France)

  • AbGenomics International, Inc. (US)

  • Alder BioPharmaceuticals,Inc. (US)

  • Amgen Inc. (US)

  • Lexicon Pharmaceuticals, Inc. (US)

  • LG Chem (South Korea)

  • OrthoTrophix, Inc. (US)

  • Tarsa Therapeutics, Inc. (US)

  • PhytoHealth Corporation (Taiwan)

  • Eisai Co., Ltd (Japan)

  • Astellas Pharma Inc. (Japan)

  • AstraZeneca (UK)

  • Baxter (US)

  • GlaxoSmithKline PLC (UK)

Report Attribute/Metric Details
  Market Size   USD 6.07 Billion
  CAGR   6.8%
  Base Year   2021
  Forecast Period   2023-2032
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   AB Science (France), AbGenomics International, Inc. (US), Alder BioPharmaceuticals,Inc. (US), Amgen Inc. (US), Lexicon Pharmaceuticals, Inc. (US), LG Chem (South Korea), OrthoTrophix, Inc. (US), Tarsa Therapeutics, Inc. (US), PhytoHealth Corporation (Taiwan), Eisai Co., Ltd (Japan), Astellas Pharma Inc. (Japan), AstraZeneca (UK), Baxter (US), GlaxoSmithKline PLC (UK)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers ·  Growing global geriatric population ·  Change in lifestyle habits leading to bad posture ·  Increasing research and development of new drugs to treat musculoskeletal disorders. ·  Rising prevalence of work-related musculoskeletal disorders. ·  Rising awareness of advanced treatment for musculoskeletal disorders. ·  Launch of new medication to manage the symptoms of chronic musculoskeletal system disorders.


Frequently Asked Questions (FAQ) :

The musculoskeletal system disorders market is projected to grow at a 6.8% CAGR between 2023-2032.

The Americas are predicted to have the largest share in the musculoskeletal system disorders market.

The musculoskeletal system disorders market is predicted to touch USD 6.07 Billion by 2032.

Key competitors in the musculoskeletal system disorders market include GlaxoSmithKline PLC (UK), Baxter (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Eisai Co., Ltd (Japan), PhytoHealth Corporation (Taiwan), Tarsa Therapeutics, Inc. (US), OrthoTrophix, Inc. (US), LG Chem (South Korea), Lexicon Pharmaceuticals, Inc. (US), Amgen Inc. (US), Alder BioPharmaceuticals,Inc. (US), AbGenomics International, Inc. (US), and AB Science (France).

High surgery cost may restrict market growth.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Request Free Sample
Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Ask for Customization